Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Key Inclusion Criteria:

- Not a candidate for fludarabine therapy based on either:

1. creatinine clearance < 70 mL/min, or

2. Cumulative Illness Rating Scale score > 6, by assessment of the investigator

- Diagnosis of B-cell CLL, with diagnosis established according to International
Workshop on Chronic Lymphocytic Leukemia (IWCLL)

- No prior therapy for CLL other than corticosteroids for disease complications.

- CLL that warrants treatment

- Presence of measurable lymphadenopathy

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

- Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
transformation)

- Known presence of myelodysplastic syndrome

- Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
randomization

- Ongoing liver injury

- Ongoing drug-induced pneumonitis

- Ongoing inflammatory bowel disease

- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

- Ongoing immunosuppressive therapy other than corticosteroids

- Concurrent participation in another therapeutic clinical trial

- Undergone major surgery within 30 days prior to randomization

- Known hypersensitivity or intolerance to any of the active substances or excipients in
the formulations for idelalisib, obinutuzumab, or chlorambucil

- History of non-infectious pneumonitis

- Received last dose of study drug on another therapeutic clinical trial within 30 days
prior to randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply.